It’s time to update your counseling on the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer; New York City). The Food and Drug Administration (FDA) has added a “black box” warning to the drug’s labeling to highlight that prolonged use may result in the loss of bone mineral density (BMD).